Poseida Therapeutics, Inc. (PSTX)
- Previous Close
2.0700 - Open
2.0300 - Bid 2.0400 x 500
- Ask 2.0700 x 400
- Day's Range
1.9800 - 2.0800 - 52 Week Range
1.5400 - 4.2700 - Volume
266,623 - Avg. Volume
734,472 - Market Cap (intraday)
197.803M - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3700 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
poseida.comRecent News: PSTX
Performance Overview: PSTX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PSTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PSTX
Valuation Measures
Market Cap
197.80M
Enterprise Value
71.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.86
Price/Book (mrq)
1.91
Enterprise Value/Revenue
1.10
Enterprise Value/EBITDA
-0.65
Financial Highlights
Profitability and Income Statement
Profit Margin
-190.76%
Return on Assets (ttm)
-25.87%
Return on Equity (ttm)
-84.75%
Revenue (ttm)
64.7M
Net Income Avi to Common (ttm)
-123.43M
Diluted EPS (ttm)
-1.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
212.2M
Total Debt/Equity (mrq)
82.37%
Levered Free Cash Flow (ttm)
-40.72M
Research Analysis: PSTX
Company Insights: PSTX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: PSTX
Daily – Vickers Top Buyers & Sellers for 08/12/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 02/17/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/16/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/15/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.